Latest Healthcare News

PainChek has secured A$5.5 million via convertible notes to accelerate its US sales expansion and strengthen working capital amid key commercial milestones.

Vitrafy Life Sciences has achieved a major validation milestone with US Army-backed Phase II results showing its no-wash platelet cryopreservation protocol delivers 94% post-thaw recovery, outperforming existing standards and advancing FDA registration plans.

Oceania Healthcare Limited has delivered a standout FY26 with 16% higher sales, 20% EBITDA growth, and a 19% reduction in net debt, setting the stage for positive cash flow in FY27 despite no dividend declared this year.

Avecho Biotechnology has wrapped up the treatment phase for its pivotal Phase III insomnia trial involving 244 participants, setting the stage for an interim efficacy analysis expected in late June 2026.

Little Green Pharma (ASX:LGP) posted a 15.3% revenue increase to AUD 42.5 million in FY2026, driven by European market expansion, yet recorded a $1.4 million loss after tax impacted by significant inventory write-downs.

Island Pharmaceuticals has appointed Raymond Taylor, a former BioCryst executive with deep Galidesivir expertise and US government funding experience, to accelerate development and procurement efforts for its broad-spectrum antiviral amid rising viral threats.

Adherium Limited plans a 1-for-100 share consolidation pending shareholder approval, aiming to reduce share count and enhance marketability.

Argenica Therapeutics has passed a critical FDA genotoxicity test for its stroke drug ARG-007, advancing its IND application and edging closer to Phase 2b clinical trials in the US and Australia.

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.

TruScreen Group Limited has kicked off a NZ$2.9 million capital raising combining a NZ$1 million placement and a NZ$1.94 million rights issue to fund its global expansion and regulatory compliance efforts. The company reported a 42% jump in product sales for FY2026 and is targeting major public health programs across 14 countries.

BLIS Technologies posted a 16% revenue increase to $14.7 million in FY26, resolving a key intellectual property dispute and expanding strategic partnerships, including an extended Probi AB agreement that now covers pet nutrition.

Mach7 Technologies has secured a five-year, A$1.7 million subscription contract with US teleradiology provider AMRADNET, slashing deployment time from 12 months to just 45 days.